ezetimibe and simvastatin
ezetimibe and simvastatin is listed in the FDA National Drug Code directory with 21 NDC codes, marketed under brand names including ezetimibe and simvastatin, VYTORIN. Available dosage form: tablet.
Drug details
- Generic Name
- ezetimibe and simvastatin
- Brand Names
- ezetimibe and simvastatin, VYTORIN
- Application Number
- ANDA208699
- Sponsor
- ORGANON PHARMA (UK) LIMITED
- NDC Codes
- 21
- Dosage Forms
- TABLET
- Routes
- ORAL
- Active Ingredients
- EZETIMIBE, SIMVASTATIN
Indications and Usage
1 INDICATIONS AND USAGE Ezetimibe and Simvastatin Tablets Ezetimibe and Simvastatin Tablets are a combination of simvastatin and ezetimibe indicated: • As an adjunct to diet to reduce elevated low density lipoprotein cholesterol (LDL-C): • In adults with primary hyperlipidemia. • In adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to other LDL-C-lowering therapies to reduce elevated LDL-C in adults with homozygous familial hypercholesterolemia (HoFH). Simvastatin Simvastatin, when used as a component of ezetimibe and simvastatin tablets, is indicated to reduce the risk of total mortality by reducing risk of coronary heart disease death, non-fatal myocardial infarction and stroke, and the need for coronary and non-coronary revascularization procedures in adults with established coronary heart disease, cerebrovascular disease, peripheral vascular disease, and/or diabetes, who are at high risk of coronary heart disease events. Ezetimibe and simvastatin tablets are a combination of ezetimibe, a dietary cholesterol absorption inhibitor, and simvastatin, an HMG-CoA reductase inhibitor (statin) indicated: ( 1 ) • As an adjunct to diet to reduce elevated low density lipoprotein cholesterol (LDL-C): • In adults with primary hyperlipidemia. • In adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to other LDL-C lowering therapies to reduce LDL-C in adults with homozygous familial hypercholesterolemia (HoFH). Simvastatin Simvastatin, when used as a component of ezetimibe and simvastatin tablets, is indicated to reduce the risk of total mortality by reducing risk of coronary heart disease death, non-fatal myocardial infarction and stroke, and the need for coronary and non-coronary revascularization procedures in adults with established coronary heart disease, cerebrovascular disease, peripheral vascular disease, and/or diabetes, who are at high risk of coronary heart disease events.